메뉴 건너뛰기
Clinical Colorectal Cancer
Volumn 4, Issue 5, 2005, Pages 300-301
The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: Interim data from the ECOG 3200 trial

(2)  Reddy, G Kesava a   Jain, Vinay K a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;
EID: 14644398030     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70131-1     Document Type: Article
Times cited : (20)
References (4)
  • 1
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Febrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
    • (2004) N. Engl. J. Med. , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Febrenbacher, L.2    Novotny, W.3
  • 2
    • 12944332507 scopus 로고    scopus 로고
    • Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11
    • (Abstract #3516)
    • Kabbinavar F, Schulz J, McCleod M, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. J Clin Oncol 2004; 22(suppl):14S (Abstract #3516).
    • (2004) J. Clin. Oncol. , vol.22 , Issue.SUPPL.
    • Kabbinavar, F.1    Schulz, J.2    McCleod, M.3
  • 3
    • 84898699269 scopus 로고    scopus 로고
    • The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200
    • Presented at the 2004 ASCO Gastrointestinal Cancers Symposium; January 22-24, San Francisco, CA. Abstract #241
    • Giantonio B, Catalano P, Meropol N, et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the 2004 ASCO Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #241.
    • (2004)
    • Giantonio, B.1    Catalano, P.2    Meropol, N.3
  • 4
    • 0043215711 scopus 로고    scopus 로고
    • Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200
    • (Abstract #975)
    • Benson AB, Catalano PJ, Meropol NJ, et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2003; 22:243 (Abstract #975).
    • (2003) Proc. Am. Soc. Clin. Oncol. , vol.22 , pp. 243
    • Benson, A.B.1    Catalano, P.J.2    Meropol, N.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.